Taiwan · Delayed Price · Currency is TWD Revivegen Statistics
Total Valuation
Revivegen has a market cap or net worth of TWD 1.86 billion. The enterprise value is 6.90 billion.
| Market Cap | 1.86B |
| Enterprise Value | 6.90B |
Important Dates
The next estimated earnings date is Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Revivegen has 60.04 million shares outstanding. The number of shares has increased by 4.17% in one year.
| Current Share Class | 60.04M |
| Shares Outstanding | 60.04M |
| Shares Change (YoY) | +4.17% |
| Shares Change (QoQ) | -5.71% |
| Owned by Insiders (%) | 5.76% |
| Owned by Institutions (%) | n/a |
| Float | 31.52M |
Valuation Ratios
The trailing PE ratio is 137.10.
| PE Ratio | 137.10 |
| Forward PE | n/a |
| PS Ratio | 4.17 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 14.30 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.66, with an EV/FCF ratio of -6.57.
| EV / Earnings | 523.75 |
| EV / Sales | 15.53 |
| EV / EBITDA | 48.66 |
| EV / EBIT | 205.38 |
| EV / FCF | -6.57 |
Financial Position
The company has a current ratio of 0.27, with a Debt / Equity ratio of 1.78.
| Current Ratio | 0.27 |
| Quick Ratio | 0.24 |
| Debt / Equity | 1.78 |
| Debt / EBITDA | 30.91 |
| Debt / FCF | -4.17 |
| Interest Coverage | 1.05 |
Financial Efficiency
Return on equity (ROE) is 0.63% and return on invested capital (ROIC) is 0.44%.
| Return on Equity (ROE) | 0.63% |
| Return on Assets (ROA) | 0.32% |
| Return on Invested Capital (ROIC) | 0.44% |
| Return on Capital Employed (ROCE) | 0.58% |
| Revenue Per Employee | 4.15M |
| Profits Per Employee | 123,178 |
| Employee Count | 107 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 102.68 |
Taxes
In the past 12 months, Revivegen has paid 2.63 million in taxes.
| Income Tax | 2.63M |
| Effective Tax Rate | 14.49% |
Stock Price Statistics
The stock price has decreased by -12.69% in the last 52 weeks. The beta is 0.28, so Revivegen's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -12.69% |
| 50-Day Moving Average | 29.54 |
| 200-Day Moving Average | 30.47 |
| Relative Strength Index (RSI) | 55.63 |
| Average Volume (20 Days) | 59,365 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Revivegen had revenue of TWD 444.40 million and earned 13.18 million in profits. Earnings per share was 0.23.
| Revenue | 444.40M |
| Gross Profit | 103.08M |
| Operating Income | 33.61M |
| Pretax Income | 18.18M |
| Net Income | 13.18M |
| EBITDA | 120.24M |
| EBIT | 33.61M |
| Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 308.19 million in cash and 4.39 billion in debt, with a net cash position of -4.08 billion or -67.91 per share.
| Cash & Cash Equivalents | 308.19M |
| Total Debt | 4.39B |
| Net Cash | -4.08B |
| Net Cash Per Share | -67.91 |
| Equity (Book Value) | 2.46B |
| Book Value Per Share | 24.77 |
| Working Capital | -1.09B |
Cash Flow
In the last 12 months, operating cash flow was 129.79 million and capital expenditures -1.18 billion, giving a free cash flow of -1.05 billion.
| Operating Cash Flow | 129.79M |
| Capital Expenditures | -1.18B |
| Free Cash Flow | -1.05B |
| FCF Per Share | -17.50 |
Margins
Gross margin is 23.20%, with operating and profit margins of 7.56% and 2.97%.
| Gross Margin | 23.20% |
| Operating Margin | 7.56% |
| Pretax Margin | 4.09% |
| Profit Margin | 2.97% |
| EBITDA Margin | 27.06% |
| EBIT Margin | 7.56% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.61%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 1.61% |
| Dividend Growth (YoY) | 149.53% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 71.88% |
| Buyback Yield | -4.17% |
| Shareholder Yield | -2.57% |
| Earnings Yield | 0.71% |
| FCF Yield | -56.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2024. It was a forward split with a ratio of 1.14.
| Last Split Date | Jul 26, 2024 |
| Split Type | Forward |
| Split Ratio | 1.14 |
Scores
Revivegen has an Altman Z-Score of 0.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.13 |
| Piotroski F-Score | 5 |